Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen

Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen

Podrobná bibliografie
Hlavní autoři:	Goss, P, Mamounas, E, Jakesz, R, Markopoulos, C, Dowsett, M, Peto, R, Godwin, J, Davies, C
Médium:	Conference item
Vydáno:	2009

Podobné jednotky

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
Autor: Dowsett, M, a další
Vydáno: (2009)

Variation in use of adjuvant tamoxifen.
Autor: Davies, C, a další
Vydáno: (1998)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
Autor: Butani D, a další
Vydáno: (2021-11-01)

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
Autor: Gelber, R, a další
Vydáno: (1996)

Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies
Autor: Ingle, J, a další
Vydáno: (2009)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
Autor: Andy Göbel, a další
Vydáno: (2019-06-01)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
Autor: Tomoya Sawada, MD, a další
Vydáno: (2023-06-01)

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
Autor: Davies, C, a další
Vydáno: (2017)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
Autor: Tas Faruk, a další
Vydáno: (2008-07-01)

Aromatase Inhibitors Reduce the Expression of a Hypoxia Metagene in Oestrogen Receptor Positive Breast Cancer in Postmenopausal Women.
Autor: Ghazoui, Z, a další
Vydáno: (2009)

Tamoxifen control arms in trials of aromatase inhibitors: possible influence on safety data
Autor: Sven Kurbel
Vydáno: (2008-08-01)

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
Autor: Davies, C
Vydáno: (2004)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
Autor: Junmei Cairns, a další
Vydáno: (2020-08-01)

Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
Autor: Rebecca Pedersini, a další
Vydáno: (2022-12-01)

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user
Autor: William T. Jaegle, a další
Vydáno: (2017-11-01)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
Autor: Eugene F. Schuster, a další
Vydáno: (2023-07-01)

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]
Autor: Davies, C, a další
Vydáno: (1998)

Five years of tamoxifen--or more?
Autor: Peto, R
Vydáno: (1996)

EFFECTS OF ADJUVANT TAMOXIFEN AND OF CYTOTOXIC THERAPY ON MORTALITY IN EARLY BREAST-CANCER - AN OVERVIEW OF 61 RANDOMIZED TRIALS AMONG 28,896 WOMEN
Autor: Peto, R
Vydáno: (1989)

Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: Beneficial effect of bisphosphonates
Autor: Pineda-Moncusí, M, a další
Vydáno: (2019)

TAMOXIFEN IN HEALTHY PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN - DIFFERENT RISKS AND BENEFITS - RESPONSE
Autor: Gray, R
Vydáno: (1994)

Are AI detection and plagiarism similarity scores worthwhile in the age of ChatGPT and other Generative AI?
Autor: Philip Baron
Vydáno: (2024-09-01)

Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
Autor: Krstić Predrag, a další
Vydáno: (2021-01-01)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
Autor: Martinez-Cannon BA, a další
Vydáno: (2021-05-01)

Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Autor: Toru Higuchi, a další
Vydáno: (2016-01-01)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
Autor: Mo QG, a další
Vydáno: (2016-11-01)

Early breast cancer: How long should tamoxifen continue?
Autor: Davies, C, a další
Vydáno: (1999)

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trialResearch in context
Autor: Vivianne C.G. Tjan-Heijnen, a další
Vydáno: (2023-04-01)

Adjuvant CMF and tamoxifen in the elderly breast cancer patients
Autor: Vrbavac Milenko, a další
Vydáno: (2002-01-01)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
Autor: Helena Record, a další
Vydáno: (2023-10-01)

Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study
Autor: Huah Shin Ng, a další
Vydáno: (2018-01-01)

[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]
Autor: Davies, C, a další
Vydáno: (1997)

Tamoxifen therapy for patients with breast cancer - Authors' reply.
Autor: Davies, C, a další
Vydáno: (2013)

Exploring Peoples' Perception of Autonomy and Reactance in Everyday AI Interactions
Autor: Supraja Sankaran, a další
Vydáno: (2021-09-01)

Impact of a Physical Exercise and Health Education Program on Metabolic Syndrome and Quality of Life in Postmenopausal Breast Cancer Women Undergoing Adjuvant Treatment with Aromatase Inhibitors
Autor: Pedro Cespedes, a další
Vydáno: (2024-11-01)

Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study
Autor: Javier García-Sánchez, a další
Vydáno: (2022-12-01)

AI for AI: Using AI methods for classifying AI science documents
Autor: Evi Sachini, a další
Vydáno: (2023-02-01)

AI vs. AI: Can AI Detect AI-Generated Images?
Autor: Samah S. Baraheem, a další
Vydáno: (2023-09-01)

Early breast cancer: How long should tamoxifen continue?
Autor: Davies, C, a další
Vydáno: (1998)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
Autor: Lundgren Steinar, a další
Vydáno: (2010-06-01)